Overview

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Status:
Active, not recruiting
Trial end date:
2021-12-12
Target enrollment:
Participant gender:
Summary
This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Male and Female Subjects being Overweight or with Obesity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.